Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Abbott Laboratories : Abbott and AbbVie Announce Investor Calls

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2013 | 04:10pm CEST

Abbott Park, Illinois and North Chicago - Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2012 financial results on Wednesday, Jan. 23, 2013, before the market opens.

Abbott's quarterly and annual results will include contributions from the company's former research-based pharmaceutical business, which became AbbVie on Jan. 1, 2013. While these results will be captured in a single press release, both companies will host separate conference calls to discuss their respective business results and 2013 outlooks.

Abbott will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) on Jan. 23, 2013. It will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

On Wednesday, Jan. 30, 2013, AbbVie will host a live webcast at 8 a.m. Central time (9 a.m. Eastern) accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

About Abbott

Abbott (NYSE: ABT) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. With its 125-year history, the company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Abbott Contacts:
Media:
Scott Stoffel

(847) 936-9502
Financial:
Brian Yoor

(847) 937-6343
AbbVie Contacts:
Media:
Adelle Infante

(847) 938-8745
Financial:
Larry Peepo

(847) 935-6722
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
05/25 ABBOTT LABORATORIES : An Application for the Trademark "EAS PRO SCIENCE" Has Bee..
05/25 ABBOTT LABORATORIES : Trademark Application for "HI-TORQUE INTERMEDIATE" Filed b..
05/25 ABBOTT LABORATORIES : Trademark Application for "WEBNOVA NEONUTRITION OPTIMIZER"..
05/25 ABBOTT LABORATORIES : An Application for the Trademark "XIENCE PRIME" Has Been F..
05/25 ABBOTT LABORATORIES : An Application for the Trademark "YUCK-O-METER" Has Been F..
05/24 ABBOTT LABORATORIES : 26 patients have died after replacing controller for Abbot..
05/24 ALERE : Announces Update on Form 10-K and Provides Preliminary Unaudited Financi..
05/23 ABBOTT LABORATORIES : Kahira Pharmaceuticals to produce Brufen for Abbott
05/22 ABBOTT LABORATORIES : Cairo Pharmaceuticals finalizes from operate Brufen produc..
05/18 ABBOTT LABORATORIES : An Application for the Trademark "FREESTYLE LIBRE" Has Bee..
More news
Sector news : Pharmaceuticals - NEC
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/24 Abbott recalls HeartMate II LVAS controller due to risk during controller exc..
05/19 Dividend Yields Also Drown In Floods
05/17 Healthcare firms fail to swim against the tide; all sectors down
05/16 Premarket analyst action - healthcare
05/13 THE OBESITY EPIDEMIC : Are Roche And Bristol-Myers Sitting On A Mighty Prospect?
Advertisement
Financials ($)
Sales 2017 26 370 M
EBIT 2017 5 716 M
Net income 2017 2 939 M
Debt 2017 16 513 M
Yield 2017 2,46%
P/E ratio 2017 25,70
P/E ratio 2018 20,67
EV / Sales 2017 3,52x
EV / Sales 2018 3,27x
Capitalization 76 265 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 48,1 $
Spread / Average Target 9,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES13.33%76 265
JOHNSON & JOHNSON10.68%343 545
ROCHE HOLDING LTD.14.88%236 038
NOVARTIS AG6.68%212 104
PFIZER INC.-1.32%191 517
MERCK & CO., INC.10.48%177 895
More Results